---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123355"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:25:50.226250+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports Q3 net loss of $9.6M; positive Phase 1a data for ABI-5366

## Summary
- Net loss of $9.6M ($1.51/share) vs $14.4M ($3.29/share) in Q3 2023; revenue of $6.8M from Gilead collaboration.
- Cash $95.0M as of Sept 30, 2024, projected to fund operations into Q1 2026.
- Positive Phase 1a interim data for ABI-5366 (HSV) supports once-weekly and once-monthly oral dosing; Phase 1b initiated.
- Phase 1b trial for ABI-4334 (HBV) ongoing, interim data expected by end of 2024.
- ABI-1179 and ABI-6250 on track to enter clinic by end of 2024.

## SEC filing metadata
- accession: 0000950170-24-123355
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024123355/0000950170-24-123355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024123355/asmb-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123355
- JSON: https://secwatch.observer/filing/0000950170-24-123355.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.